Skip to main content
P

Precision Biosensor Inc. — Investor Relations & Filings

Ticker · 335810 ISIN · KR7335810008 KO Manufacturing
Open in API
Filings indexed 172 across all filing types
Latest filing 2024-03-18 Audit Report / Informat…
Country KR South Korea
Listing KO 335810

About Precision Biosensor Inc.

https://precision-bio.com/

Precision Biosensor Inc. is an in vitro diagnostics (IVD) company that develops, manufactures, and commercializes clinical diagnostic solutions. The company specializes in point-of-care testing (POCT), providing optimized systems for on-site diagnosis. Its product portfolio includes analyzing devices and diagnostic reagents for both human and animal health. Precision Biosensor utilizes advanced technologies, such as time-resolved fluorescence (TRF), for the sensitive and accurate detection of various disease biomarkers in immuno-diagnosis and clinical chemistry applications, including cardiac markers.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a regulatory filing from the Korea Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of financial data, audit opinions, and key financial metrics (assets, liabilities, revenue, profit/loss) for the fiscal year. While it contains financial data, it is a standardized regulatory disclosure form announcing the receipt and submission of the audit report rather than the full, multi-page audited financial statement document itself. Therefore, it falls under the category of a regulatory filing announcement. FY 2023
2024-03-18 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Precision Bio. It contains the meeting agenda, date, location, and detailed information regarding the items to be voted on, including financial statement approval, director appointments, and remuneration limits. This document is a formal notice sent to shareholders to provide information and request votes for the upcoming Annual General Meeting, which fits the definition of a Proxy Solicitation & Information Statement.
2024-03-11 Korean
주주총회집중일개최사유신고
AGM Information Classification · 1% confidence The document is a formal regulatory filing submitted to the Korea Exchange (KRX) regarding the 'Reason for holding a General Meeting of Shareholders on a concentrated date'. It explains why the company scheduled its AGM on a date that coincides with other companies' meetings. Since this is a specific regulatory disclosure regarding corporate governance and meeting scheduling that does not fit into the other specific categories like AGM-R (presentation materials) or PSI (proxy solicitation), it is best classified as a general regulatory filing.
2024-03-11 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for Precision Bio. It outlines the date, location, and specific agenda items (such as financial statement approval, director appointments, and stock option grants). This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon.
2024-03-07 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 1% confidence The document is a regulatory filing from a Korean company (Precision Biosensor) regarding a significant change in financial structure (30% or more change in revenue or profit). This type of disclosure is a standard regulatory requirement in the Korean market (DART system) to inform investors of material financial changes before the final audit is completed. It fits the definition of a general regulatory announcement regarding financial performance. FY 2023
2024-02-28 Korean
전환사채(해외전환사채포함)발행후만기전사채취득 (제1회차)
Capital/Financing Update Classification · 1% confidence The document is a regulatory filing from a Korean company (Precision Bioscience) regarding the 'Acquisition of Convertible Bonds before Maturity'. This type of filing details changes to the company's capital structure and debt obligations, specifically the early redemption of convertible bonds. According to the provided definitions, this falls under 'Capital/Financing Update' (CAP) as it relates to financing activities and changes in capital structure.
2024-02-19 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.